High CTLA-4 expression correlates with poor prognosis in thymoma patients

Giorgio Santoni, Consuelo Amantini, Maria Beatrice Morelli, Daniele Tomassoni, Matteo Santoni, Oliviero Marinelli, Massimo Nabissi, Claudio Cardinali, Vittorio Paolucci, Mariangela Torniai, Silvia Rinaldi, Francesca Morgese, Giovanni Bernardini, Rossana Berardi

Research output: Contribution to journalArticle

Abstract

Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the progression of different types of tumors, it has emerged as a potential therapeutic target in cancer patients. In this study, we assessed the expression of CTLA-4 both at mRNA and protein levels in paraffin embedded-tissues from patients with thymomas. Furthermore, we evaluated the relationship between CTLA-4 expression and the clinical-pathologic characteristics and prognosis in patients with thymomas. Sixty-eight patients with median age corresponding to 62 years were included in this analysis. Thymomas were classified accordingly to the WHO and Masaoka-Koga for histochemical analysis and for prognostic significance. A statistical difference was found between CTLA-4 mRNA levels in human normal thymus compared with thymoma specimens. CTLA-4 expression was statistically found to progressively increase in A, B1, B2, AB and it was maximal in B3 thymomas. According to Masaoka-Koga pathological classification, CTLA-4 expression was lower in I, IIA and IIB, and higher in invasive III and IV stages. By confocal microscopy analysis we identified the expression of CTLA-4 both in tumor cells and in CD45+ tumor-infiltrating leukocytes, mainly in B3 and AB thymomas. Finally, CTLA-4 overexpression significantly correlates with reduced overall survival in thymoma patients and in atypical thymoma subgroup, suggesting that it represents a negative prognostic factor.

Original languageEnglish
Pages (from-to)16665-16677
Number of pages13
JournalOncotarget
Volume9
Issue number24
DOIs
Publication statusPublished - Mar 30 2018

Fingerprint

Thymoma
Neoplasms
Thymus Gland
Mediastinal Neoplasms
CTLA-4 Antigen
Messenger RNA
Confocal Microscopy
Paraffin
Leukocytes
Epithelial Cells
T-Lymphocytes
Survival
Incidence

Cite this

Santoni, G., Amantini, C., Morelli, M. B., Tomassoni, D., Santoni, M., Marinelli, O., ... Berardi, R. (2018). High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget, 9(24), 16665-16677. https://doi.org/10.18632/oncotarget.24645

High CTLA-4 expression correlates with poor prognosis in thymoma patients. / Santoni, Giorgio; Amantini, Consuelo; Morelli, Maria Beatrice; Tomassoni, Daniele; Santoni, Matteo; Marinelli, Oliviero; Nabissi, Massimo; Cardinali, Claudio; Paolucci, Vittorio; Torniai, Mariangela; Rinaldi, Silvia; Morgese, Francesca; Bernardini, Giovanni; Berardi, Rossana.

In: Oncotarget, Vol. 9, No. 24, 30.03.2018, p. 16665-16677.

Research output: Contribution to journalArticle

Santoni, G, Amantini, C, Morelli, MB, Tomassoni, D, Santoni, M, Marinelli, O, Nabissi, M, Cardinali, C, Paolucci, V, Torniai, M, Rinaldi, S, Morgese, F, Bernardini, G & Berardi, R 2018, 'High CTLA-4 expression correlates with poor prognosis in thymoma patients', Oncotarget, vol. 9, no. 24, pp. 16665-16677. https://doi.org/10.18632/oncotarget.24645
Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O et al. High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget. 2018 Mar 30;9(24):16665-16677. https://doi.org/10.18632/oncotarget.24645
Santoni, Giorgio ; Amantini, Consuelo ; Morelli, Maria Beatrice ; Tomassoni, Daniele ; Santoni, Matteo ; Marinelli, Oliviero ; Nabissi, Massimo ; Cardinali, Claudio ; Paolucci, Vittorio ; Torniai, Mariangela ; Rinaldi, Silvia ; Morgese, Francesca ; Bernardini, Giovanni ; Berardi, Rossana. / High CTLA-4 expression correlates with poor prognosis in thymoma patients. In: Oncotarget. 2018 ; Vol. 9, No. 24. pp. 16665-16677.
@article{35bf9b7b862b4fafa4f247dd61525274,
title = "High CTLA-4 expression correlates with poor prognosis in thymoma patients",
abstract = "Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the progression of different types of tumors, it has emerged as a potential therapeutic target in cancer patients. In this study, we assessed the expression of CTLA-4 both at mRNA and protein levels in paraffin embedded-tissues from patients with thymomas. Furthermore, we evaluated the relationship between CTLA-4 expression and the clinical-pathologic characteristics and prognosis in patients with thymomas. Sixty-eight patients with median age corresponding to 62 years were included in this analysis. Thymomas were classified accordingly to the WHO and Masaoka-Koga for histochemical analysis and for prognostic significance. A statistical difference was found between CTLA-4 mRNA levels in human normal thymus compared with thymoma specimens. CTLA-4 expression was statistically found to progressively increase in A, B1, B2, AB and it was maximal in B3 thymomas. According to Masaoka-Koga pathological classification, CTLA-4 expression was lower in I, IIA and IIB, and higher in invasive III and IV stages. By confocal microscopy analysis we identified the expression of CTLA-4 both in tumor cells and in CD45+ tumor-infiltrating leukocytes, mainly in B3 and AB thymomas. Finally, CTLA-4 overexpression significantly correlates with reduced overall survival in thymoma patients and in atypical thymoma subgroup, suggesting that it represents a negative prognostic factor.",
author = "Giorgio Santoni and Consuelo Amantini and Morelli, {Maria Beatrice} and Daniele Tomassoni and Matteo Santoni and Oliviero Marinelli and Massimo Nabissi and Claudio Cardinali and Vittorio Paolucci and Mariangela Torniai and Silvia Rinaldi and Francesca Morgese and Giovanni Bernardini and Rossana Berardi",
year = "2018",
month = "3",
day = "30",
doi = "10.18632/oncotarget.24645",
language = "English",
volume = "9",
pages = "16665--16677",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "24",

}

TY - JOUR

T1 - High CTLA-4 expression correlates with poor prognosis in thymoma patients

AU - Santoni, Giorgio

AU - Amantini, Consuelo

AU - Morelli, Maria Beatrice

AU - Tomassoni, Daniele

AU - Santoni, Matteo

AU - Marinelli, Oliviero

AU - Nabissi, Massimo

AU - Cardinali, Claudio

AU - Paolucci, Vittorio

AU - Torniai, Mariangela

AU - Rinaldi, Silvia

AU - Morgese, Francesca

AU - Bernardini, Giovanni

AU - Berardi, Rossana

PY - 2018/3/30

Y1 - 2018/3/30

N2 - Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the progression of different types of tumors, it has emerged as a potential therapeutic target in cancer patients. In this study, we assessed the expression of CTLA-4 both at mRNA and protein levels in paraffin embedded-tissues from patients with thymomas. Furthermore, we evaluated the relationship between CTLA-4 expression and the clinical-pathologic characteristics and prognosis in patients with thymomas. Sixty-eight patients with median age corresponding to 62 years were included in this analysis. Thymomas were classified accordingly to the WHO and Masaoka-Koga for histochemical analysis and for prognostic significance. A statistical difference was found between CTLA-4 mRNA levels in human normal thymus compared with thymoma specimens. CTLA-4 expression was statistically found to progressively increase in A, B1, B2, AB and it was maximal in B3 thymomas. According to Masaoka-Koga pathological classification, CTLA-4 expression was lower in I, IIA and IIB, and higher in invasive III and IV stages. By confocal microscopy analysis we identified the expression of CTLA-4 both in tumor cells and in CD45+ tumor-infiltrating leukocytes, mainly in B3 and AB thymomas. Finally, CTLA-4 overexpression significantly correlates with reduced overall survival in thymoma patients and in atypical thymoma subgroup, suggesting that it represents a negative prognostic factor.

AB - Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the progression of different types of tumors, it has emerged as a potential therapeutic target in cancer patients. In this study, we assessed the expression of CTLA-4 both at mRNA and protein levels in paraffin embedded-tissues from patients with thymomas. Furthermore, we evaluated the relationship between CTLA-4 expression and the clinical-pathologic characteristics and prognosis in patients with thymomas. Sixty-eight patients with median age corresponding to 62 years were included in this analysis. Thymomas were classified accordingly to the WHO and Masaoka-Koga for histochemical analysis and for prognostic significance. A statistical difference was found between CTLA-4 mRNA levels in human normal thymus compared with thymoma specimens. CTLA-4 expression was statistically found to progressively increase in A, B1, B2, AB and it was maximal in B3 thymomas. According to Masaoka-Koga pathological classification, CTLA-4 expression was lower in I, IIA and IIB, and higher in invasive III and IV stages. By confocal microscopy analysis we identified the expression of CTLA-4 both in tumor cells and in CD45+ tumor-infiltrating leukocytes, mainly in B3 and AB thymomas. Finally, CTLA-4 overexpression significantly correlates with reduced overall survival in thymoma patients and in atypical thymoma subgroup, suggesting that it represents a negative prognostic factor.

U2 - 10.18632/oncotarget.24645

DO - 10.18632/oncotarget.24645

M3 - Article

C2 - 29682176

VL - 9

SP - 16665

EP - 16677

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -